<svg height="420" viewBox="0 0 1152 420" width="1152" xmlns="http://www.w3.org/2000/svg"><g fill="#fff" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std" font-size="23"><text><tspan x="0" y="17">In the EU, EVRENZO (roxadustat) is indicated for</tspan><tspan x="0" y="51">treatment of adult patients with symptomatic anaemia</tspan><tspan x="0" y="85">associated with chronic kidney disease (CKD)</tspan><tspan baseline-shift="7.66590013166" font-size="13.416" y="85">3</tspan></text><text transform="translate(0 113)"><tspan x="0" y="17">1. Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253–266.</tspan><tspan x="0" y="51">2. Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125–133.</tspan><tspan x="0" y="85">3. EVRENZO EU SmPC, September 2022.</tspan></text><text transform="translate(0 339)"><tspan x="0" y="17">MAT-NL-EVZ-2022-XXXXX</tspan><tspan x="0" y="46">Date of preparation: October 2022</tspan><tspan x="0" y="75">Date of expiry: October 2022</tspan></text><text transform="translate(0 226)"><tspan x="0" y="17">This information is intended for international Healthcare Professionals and was created by Astellas Pharma Inc.</tspan><tspan x="0" xml:space="preserve" y="51">    This medication is subject to additional monitoring.</tspan><tspan x="0" y="85">EVRENZO™ is only available by prescription.</tspan></text></g><path d="m10.5 0 10.5 19h-21z" transform="matrix(-1 0 0 -1 21 278)"/></svg>